WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received regulatory approval by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic Injection (ferric pyrophosphate citrate sodium sulfate co-precipitate hydrate injection) marketed in the United States as Triferic AVNU (ferric pyrophosphate citrate injection) for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.
Jeil Pharmaceutical has recently opened a new technology research centre in Yongin, Gyeonggi Province.The new research centre is part of the company’s plans to strengthen investment in the R&D sector and enhance the development of new drugs and generics.
On May 20, 2016, the Mumbai Patent Office (MPO) issued an Order refusing JE IL Pharmaceutical Co., Ltd.’s (referred to herein as the “Applicant” or “JE IL Pharma”) patent relating “Novel Tricyclic derivative”. Notably, the United States Patent and Trademark Office (PTO) issued the patent to the Applicant for the covered invention immediately prior to the filing of the Indian Patent Application.